Biotech Values

[ghmm]

UniQure (QURE)

Its been a while since I posted about why I was buying and the price is lower than when I first started buying. Still the stock has been doing quite well of late. Even before DMTX reported (questionable) data in their program. I think it is because the street is starting to realize there is a place for their Hemophilia GT.

While the High dose Hemophilia B data was not what I had hoped (in terms of FIX) the data appears to certainly be more than adequate in terms of providing efficacy and durability with no major safety concern to date. To me the stock could go much higher on just the Hemophilia program the short term key will be how their meeting with FDA goes and what type of guidance is given. If FDA signs off on a reasonable duration and size the company should do quite well even if they only get 10-20% (and it could be much higher considering what I posted earlier) of the GT hemophilia B market this could be generating a few hundred million annually in the not-to-distant future.